Supplementary Figure 2 from EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma
S
uppl
ement
a
r
yF
i
g.
2

A

B

C.
